课题基金 / 基金详情

Development of a plant-derived virus-like particle vaccine against SARS-CoV

Development of a plant-derived virus-like particle vaccine against SARS-CoV
开发针对 SARS-CoV 的植物源病毒样颗粒疫苗
批准号:
7576115
负责人:
Brenda G Hogue
金额:
$22.65万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-03-01 至 2011-02-28

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):严重急性呼吸系统综合征(SARS)是由一种新出现的冠状病毒引起的。在2002/2003年爆发期间,该疾病在国际上传播,导致总体死亡率约为10%,老年人的死亡率明显更高,约为40%。与其他冠状病毒一样,刺突(S)蛋白是中和抗体的主要靶标。SARS-CoV S蛋白通过其受体结合域(RBD)与受体血管紧张素转换酶2(ACE 2)结合。RBD具有免疫原性,是主要的中和决定簇。大量的研究已经指向疫苗的开发,但还没有可用的。人们仍然担心未来可能爆发SARS。这种病毒的宿主尚未查明。SARS-CoV是生物防御C类优先病原体。也有可能发生实验室获得性感染。因此,开发有效的疫苗仍然具有重要意义。该项目的长期目标是确定植物来源的病毒样颗粒呈现SARS-CoV S蛋白的RBD是否可以有效地刺激针对SARS-CoV的保护性系统和粘膜免疫。展示RBD的新型异源VLP将通过在植物中将RBD表达为与乙型肝炎B表面(HBsAg)和核心(HBcAg)抗原的融合体来产生。将评价含RBD的VLP在小鼠中引发强烈的全身和粘膜SARS-CoV中和抗体应答和保护性免疫的能力。将使用标准分子生物学、生物化学方法、疫苗接种和免疫学测定。该项目的具体目标是:1。在植物中产生呈递SARS-CoV S RBD的异源VLP;和2.评价植物源性VLP在小鼠模型中的免疫原性和保护效力。 公共卫生相关性:由新型冠状病毒(SARS-CoV)引起的严重急性呼吸综合征(SARS)是2002/2003年出现的新疾病,其在全球范围内造成了大量的感染和死亡,其中老年人的死亡率至少为40%。尽管全球疫情得到控制,但人们担心该病毒会再次出现,或可能被用作生物恐怖主义制剂,因此开发安全有效的疫苗至关重要。该项目的长期目标是开发一种新的亚单位疫苗,增强对SARS冠状病毒的保护作用。
英文摘要
DESCRIPTION (provided by applicant): Severe acute respiratory syndrome (SARS) is caused by a newly emerged coronavirus. During the outbreak in 2002/2003 the disease spread internationally resulting in an overall mortality rate of ~10% and a significantly higher rate of ~40% for elderly individuals. As is the case with other coronaviruses, the spike (S) protein is the major target for neutralizing antibodies. SARS-CoV S protein binds to the receptor, angiotensin-converting enzyme 2 (ACE2), through its receptor binding domain (RBD). The RBD is immunogenic and is a major neutralizing determinant. Significant research has been directed toward vaccine development, but none is yet available. Concerns remain over the possibility of future outbreaks of SARS. The reservoir for the virus has not been identified. SARS-CoV is a Biodefense Category C priority pathogen. There is also the potential for laboratory acquired infections. Thus, development of effective vaccines is still of significant importance. The long-term goal of this project is to determine if plant-derived virus-like particles presenting the RBD of the SARS-CoV S protein can efficiently stimulate protective systemic and mucosal immunity against SARS-CoV. Novel heterologous VLPs displaying the RBD will be generated by expressing the RBD as fusions with the hepatitis B surface (HBsAg) and core (HBcAg) antigens in plants. RBD-containing VLPs will be evaluated for their ability to elicit strong systemic and mucosal SARS-CoV-neutralizing antibody responses and protective immunity in mice. Standard molecular biology, biochemical approaches, vaccination and immunological assays will be used. The specific aims of the project are: 1. To produce heterologous VLPs presenting the SARS-CoV S RBD in plants; and 2. To evaluate the immunogenicity and protective efficacy of plant-derived VLPs in mouse models. PUBLIC HEALTH RELEVANCE: Severe acute respiratory syndrome (SARS) caused by a new coronavirus (SARS-CoV) is new disease that appeared in 2002/2003 which caused a significant number of infections and deaths worldwide, with a mortality rate of at least 40% in older individuals. Even though the global outbreak was contained, there are concerns that the virus will reemerge or that it could potentially be used as a bioterrorist agent, thus it is important to develop safe effective vaccines. The long term goal of this project is to develop a novel subunit vaccine that elicits protection against SARS coronavirus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金